Navigation Links
Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
Date:11/5/2009

ated symptoms or increased survival with Vectibix. Vectibix has not shown a treatment benefit for patients whose tumors had KRAS mutations in codon 12 or 13.

In December 2007, the EMEA granted a conditional marketing authorization for Vectibix as monotherapy for the treatment of patients with EGFR-expressing mCRC with wild-type KRAS genes after failure of standard chemotherapy regimens. Vectibix has been launched in over 20 countries, Switzerland, Australia and Canada. Applications in the rest of the world are pending.

Important Product Safety Information

Dermatologic Toxicity: Dermatologic toxicities occurred in 89 percent of patients and were severe (NCI-CTC grade 3 and higher) in 12 percent of patients receiving Vectibix monotherapy. Withhold Vectibix for dermatologic toxicities that are grade 3 or higher or are considered intolerable. If toxicity does not improve to </= grade 2 within 1 month, permanently discontinue Vectibix. The clinical manifestations included, but were not limited to, dermatitis acneiform, pruritus, erythema, rash, skin exfoliation, paronychia, dry skin, and skin fissures. Subsequent to the development of severe dermatologic toxicities, infectious complications, including sepsis, septic death, and abscesses requiring incisions and drainage were reported.

Infusion Reactions: Severe infusion reactions occurred in approximately 1 percent of patients. Severe infusion reactions included anaphylactic reactions, bronchospasm, and hypotension. Although not reported with Vectibix, fatal infusion reactions have occurred with other monoclonal antibody products. Stop infusion if a severe infusion reaction occurs. Depending on the severity and/or persistence of the reaction, permanently discontinue Vectibix.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one o
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Call for Applications: The Amgen Award for Science Teaching Excellence
2. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
3. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
4. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
5. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
6. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
7. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
8. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
9. Medarex to Receive Milestone Payment from Amgen
10. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
11. Reminder Webcast Alert: Transgenomic, Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... HILL, Conn. , July 29, 2014 Numotion,s ... 2014, Mike Swinford will be the company,s new ... a highly successful 22-year career at GE where he worked ... million in annual revenue to over $5 billion. His most ... Global Services. "I am thrilled to join ...
(Date:7/29/2014)... Fla. , July 29, 2014 /PRNewswire-iReach/ -- ... service provider, has launched its Medical Equipment ...  These services are tailored to the cruise ... standards prompted industry operators to propose that they ... MHG Medical,s new program is intended to create ...
(Date:7/29/2014)... 29, 2014  Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Chemistry (AACC) 2014 Clinical Lab Expo today by unveiling ... ways Roche is partnering with customers to redefine the ... us every day that they,re looking for a partner ... their labs and offices," said Jack Phillips , ...
Breaking Medicine Technology:Numotion Names Mike Swinford CEO 2MHG Medical Management Services Aims to Change Cruise Industry Standard With New Equipment Maintenance Program 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4
... Schering-Plough Corporation,(NYSE: SGP ) today reported that ... Phase II study of boceprevir, its investigational oral ... chronic,hepatitis C virus (HCV) genotype 1 were presented ... for the Study of the Liver (EASL). The,ongoing ...
... Into New Promising Drugs to Combat Hepatitis ... C ... Stem Cells of Potential Benefit in Liver Transplantation, ... At today,s sessions of the 43rd Annual Meeting of the European,Association for the ...
Cached Medicine Technology:Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 2Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 3Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 4Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 5Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 6Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 7Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 8Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 9Basic Science Discoveries Yield Progress in Hepatology 2Basic Science Discoveries Yield Progress in Hepatology 3Basic Science Discoveries Yield Progress in Hepatology 4
(Date:7/29/2014)... TUESDAY, July 29, 2014 (HealthDay News) --,The time at ... affect their chances for survival, new research suggests. ... weekends or during holidays is associated with a 13 ... business hours, researchers report. Every year, more than ... most severe type of heart attack, which is caused ...
(Date:7/29/2014)... July 29, 2014 (HealthDay News) -- Chlorine helps keep ... more likely to develop eye infections, doctors say. ... as well as blurry vision, said Dr. Sampson Davis, ... in New Jersey. It,s important to understand why ... washes away the outer film layer of the eye ...
(Date:7/29/2014)... 29, 2014 The Board of Governors of ... Hart LLP ’s Connie Akridge to serve as ... as President of the Foundation. Akridge served as President of ... a partner at Holland & Hart in Las Vegas, providing ... matters to insurance and healthcare clients for more than 25 ...
(Date:7/29/2014)... 2014 Tylenol lawsuits ( http://www.tylenollawsuitclaims.com/ ... suffered serious liver injuries due to the acetaminophen ... a multidistrict litigation underway in U.S. District Court, ... According to an Order dated July 23rd, the ... bellwether case and discovery issues. Among other things, ...
(Date:7/29/2014)... Dennis Thompson HealthDay Reporter ... healthy diet and good sleep can protect the body against ... process at a cellular level, researchers report. A study ... linked to increased shortening of telomeres, the protective caps at ... "We found that over a one-year period, the more ...
Breaking Medicine News(10 mins):Health News:Heart Attack Patients Treated at Night, Weekends May Have Worse Outcomes 2Health News:Protect Your Eyes When Hitting the Pool 2Health News:Holland & Hart LLP Attorney Connie Akridge Reappointed Trustee of the Nevada Bar Foundation 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:Healthy Habits May Slow Cellular Signs of Aging, Study Finds 2Health News:Healthy Habits May Slow Cellular Signs of Aging, Study Finds 3
... As the United States moves toward the goal of ... from the Regenstrief Institute provides a framework for evaluating the ... as the health internet. The study, which appears ... American Medical Informatics Association , also reports on the initial ...
... ... resource deployment through enhanced territory alignment , ... (PRWEB) May 11, 2010 -- The TerrAlign Group, Inc. a ... the inaugural launch of Veeva System’s Veeva Web™ program. Inclusion in this program ...
... So often the rare informs the common. Penn researchers ... have shown that it may be related to epileptic and ... A team of researchers from the University of Pennsylvania School ... professor of Neurology and director of the Penn Epilepsy Center, ...
... Oklahoma, Massachusetts asked to pull back products , TUESDAY, ... E.coli-tainted lettuce expanded late Monday as another food company ... farm currently under investigation by the U.S. Food and ... , According to the Associated Press , California-based ...
... Only ... ... KWizCom, a leading provider of critical SharePoint components to over 3,000 organizations around the ... giant AT&T. KWizCom’s Mobile Extensions , a smart phone connector that permits intelligent, ...
... Canvas Provides Health ... On Mobile Devices. , , ... Herndon, VA (PRWEB) May 11, 2010 -- Canvas announced today it had released ... HITECH compliant mobile applications on the Canvas service. The Health Insurance Portability and ...
Cached Medicine News:Health News:Measuring success: Regenstrief helps assess value of investment in health info tech 2Health News:TerrAlign Selected to Join Veeva System's Veeva Web Program 2Health News:TerrAlign Selected to Join Veeva System's Veeva Web Program 3Health News:TerrAlign Selected to Join Veeva System's Veeva Web Program 4Health News:Rare disease in Amish children sheds light on common neurological disorders 2Health News:Tainted Lettuce Recall Expands 2Health News:Tainted Lettuce Recall Expands 3Health News:KWizCom's Mobile Extensions for SharePoint Receive AT&T Certified Solutions Status 2Health News:HIPAA HITECH Compliant Mobile Apps Available for Android, Blackberry and Windows Mobile Smartphones 2Health News:HIPAA HITECH Compliant Mobile Apps Available for Android, Blackberry and Windows Mobile Smartphones 3Health News:HIPAA HITECH Compliant Mobile Apps Available for Android, Blackberry and Windows Mobile Smartphones 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: